Lenograstim


Thông tin thuốc gốc
Chỉ định và Liều dùng
Intravenous, Subcutaneous
Neutropenia following bone marrow transplantation
Adult: 150 mcg/m2 (19.2 million IU/m2) daily given via IV infusion over 30 minutes or via SC inj, to be started the day (not less than 24 hours) after transplantation and continued until the expected nadir has passed and the neutrophil count has stabilised. Max duration: 28 days.
Child: >2 years Same as adult dose.

Subcutaneous
Mobilisation of peripheral blood progenitor cells for autologous peripheral blood stem cell transplantation
Adult: As monotherapy: 10 mcg/kg (1.28 million IU/kg) daily for 4-6 days (5-6 days in healthy donors). After myelosuppressive chemotherapy: 150 mcg/m2 (19.2 million IU/m2) daily, to be started 1-5 days after completion of chemotherapy and continued until the neutrophil count has stabilised.

Subcutaneous
Chemotherapy-induced neutropenia
Adult: 150 mcg/m2 (19.2 million IU/m2) daily, to be started on the day (not less than 24 hours) after the last dose of antineoplastic and continued until the expected nadir has passed and the neutrophil count has stabilised. Max duration: 28 days.
Child: >2 years Same as adult dose.
Hướng dẫn pha thuốc
Dilute the contents of the vial with the contents of 1 ampoule of the solvent provided (water for inj). Shake gently for approx 5 seconds until it is completely dissolved. Do not shake vigorously. For IV infusion, dilute further with an appropriate amount of Na chloride 0.9% solution or in dextrose 5% solution as instructed in product labelling.
Chống chỉ định
Myeloid malignancy other than de novo acute myeloid leukaemia, de novo acute myeloid leukaemia aged <55 years, de novo acute myeloid leukaemia with good cytogenetics. Do not use 24 hours before to 24 hours after administration of cytotoxic chemotherapy.
Thận trọng
Patient with pre-malignant myeloid condition, recent history of pulmonary infiltrates or pneumonia, sickle cell trait or sickle cell disease; known risk factors for thrombosis (including donors). Children. Pregnancy and lactation.
Tác dụng không mong muốn
Significant: Leucocytosis, apheresis-related thrombocytopenia, venous thromboembolism (e.g. DVT, pulmonary embolism), arterial thromboembolism (e.g. MI, cerebrovascular event), splenomegaly, glomerulonephritis. Rarely, aortitis, splenic rupture. Very rarely, allergic reactions including anaphylaxis, cutaneous vasculitis.
Gastrointestinal disorders: Stomatitis, diarrhoea, nausea, vomiting, abdominal pain.
General disorders and administration site conditions: Fever, asthenia, pain.
Infections and infestations: Sepsis.
Investigations: Increased AST, ALT, alkaline phosphatase, lactate dehydrogenase.
Musculoskeletal and connective tissue disorders: Bone pain, back pain.
Nervous system disorders: Headache.
Skin and subcutaneous tissue disorders: Rash, alopecia. Very rarely, Sweet's syndrome, erythema nodosum, pyoderma gangrenosum, Lyell's syndrome.
Potentially Fatal: Pulmonary infiltrates leading to respiratory failure or acute respiratory distress syndrome (ARDS), capillary leak syndrome.
Chỉ số theo dõi
Monitor WBC with differential and platelets frequently during therapy and as clinically necessary; urinalysis, spleen size. Monitor for signs or symptoms of allergic reactions, aortitis, capillary leak syndrome, cutaneous vasculitis, respiratory distress syndrome, and splenic rupture.
Tương tác
May enhance the toxicity of antineoplastic agents (e.g. nitrosoureas, mitomycin); do not use lenograstim 24 hours before to 24 hours after chemotherapy ends.
Tác dụng
Description: Lenograstim is a recombinant human granulocyte-colony stimulating factor (rhG-CSF) that belongs to the cytokine group of biologically active proteins. It stimulates the production, maturation and activation of neutrophils thereby increasing peripheral neutrophil counts.
Onset: Within 24 hours.
Pharmacokinetics:
Absorption: Bioavailability: 30%.
Distribution: Volume of distribution: Approx 1 L/kg.
Metabolism: Metabolised to peptides.
Excretion: Via urine (<1%, as unchanged drug). Elimination half-life: 1-1.5 hours (IV); 3-4 hours (SC).
Bảo quản
Store below 30°C. Do not freeze.
Phân loại MIMS
Các tác nhân tạo máu
Phân loại ATC
L03AA10 - lenograstim ; Belongs to the class of colony stimulating factors. Used as immunostimulants.
Tài liệu tham khảo
Anon. Lenograstim. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 19/08/2022.

Buckingham R (ed). Lenograstim. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 19/08/2022.

Granocyte 33.6 MIU = 263 µg Lyophilised Powder for Injection SC/IV Infusion (Sanofi Winthrop Industrie). MIMS Philippines. http://www.mims.com/philippines. Accessed 19/08/2022.

Joint Formulary Committee. Lenograstim. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 19/08/2022.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Lenograstim từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2022 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in